Premium
Weekly cisplatin and radiotherapy for low risk, locoregionally advanced human papillomavirus–positive oropharyngeal squamous cell carcinoma
Author(s) -
Urban Damien,
Corry June,
Solomon Ben,
Lim Annette M.,
Fua Tsien,
Coleman Andrew,
D'Costa Ieta,
Tiong Albert,
Liu Chen,
Peters Lester J.,
Rischin Danny
Publication year - 2016
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.24169
Subject(s) - mucositis , medicine , radiation therapy , neutropenia , cisplatin , human papillomavirus , oncology , gastroenterology , chemotherapy
Abstract Background There is interest in different treatment strategies, including deintensification in good prognosis human papillomavirus‐positive (HPV(+)) oropharyngeal squamous cell carcinoma (SCC). We reviewed our experience with weekly cisplatin in low‐risk, locoregionally advanced HPV(+) oropharyngeal SCC since late 2009. Methods Data from patients with low‐risk HPV(+) oropharyngeal SCC treated with weekly cisplatin (40 mg/m 2 ) and 70 Gy radiotherapy were collected. Low risk was defined as stage III to IV oropharyngeal SCC excluding T1‐2N1, T4 or N3 disease, or N2b to N2c disease in patients with >10 pack‐year smoking history. Results Of 31 patients, the median age was 56 years (range, 41–69 years). All patients completed 70 Gy radiotherapy within 51 days and 84% completed at least 5 cycles of cisplatin. Grade 3 mucositis occurred in 22 patients (71%) and grade 3 febrile neutropenia in 6 patients (19%). No patients required enteral feeding at 12 months. The median follow‐up was 30 months (range, 21–57 months) with no recurrences or deaths. Conclusion Concurrent weekly cisplatin is relatively well‐tolerated and associated with excellent disease control in low‐risk, locoregionally advanced HPV(+) oropharyngeal SCC. © 2015 Wiley Periodicals, Inc. Head Neck 38 : E1117–E1121, 2016